Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.
- Conditions
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02165046
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 90
- Registration Number
- NCT02069847
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Comparison Between Budesonide and Dexamethasone Treatments for Respiratory Discomfort After Extubation on Children
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 70
- Registration Number
- NCT02056379
- Locations
- 🇧🇷
Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP), São Paulo, Brazil
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT02055352
- Locations
- 🇵🇦
Novartis Investigative Site, Panama City, Panamá, Panama
Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT02024659
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Curosurf/Budesonide for Infants With Respiratory Distress Syndrome
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 300
- Registration Number
- NCT02013115
- Locations
- 🇨🇳
Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China
Does Asthma Phenotype Have Impact on Disease Control
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01978678
- Locations
- 🇩🇰
Respiratory research unit, Bispebjerg University Hospital, Copenhagen, Denmark
🇩🇰Department of Respiratory Medicine, L, Bispebjerg Hospital,, Copenhagen, NV, Denmark
Asthma Biomarkers for Predicting Response to Therapy
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 148
- Registration Number
- NCT01973751
- Locations
- 🇨🇳
Department of Respiratory and Critical Care Medicine, Tongji Hospital, Wuhan, Hubei, China
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT01955980
- Locations
- 🇩🇪
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany
🇩🇪University Göttingen, Göttingen, Germany
🇩🇪University Munich, Munich, Germany
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT01950507
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.